Quantitative and qualitative differences in subcutaneous adipose tissue stores across lipodystrophy types shown by magnetic resonance imaging
© Al-Attar et al; licensee BioMed Central Ltd. 2007
Received: 22 November 2006
Accepted: 12 March 2007
Published: 12 March 2007
Lipodystrophies are characterized by redistributed subcutaneous fat stores. We previously quantified subcutaneous fat by magnetic resonance imaging (MRI) in the legs of two patients with familial partial lipodystrophy subtypes 2 and 3 (FPLD2 and FPLD3, respectively). We now extend the MRI analysis across the whole body of patients with different forms of lipodystrophy.
We studied five subcutaneous fat stores (supraclavicular, abdominal, gluteal, thigh and calf) and the abdominal visceral fat stores in 10, 2, 1, 1 and 2 female subjects with, respectively, FPLD2, FPLD3, HIV-related partial lipodystrophy (HIVPL), acquired partial lipodystrophy (APL), congenital generalized lipodystrophy (CGL) and in six normal control subjects.
Compared with normal controls, FPLD2 subjects had significantly increased supraclavicular fat, with decreased abdominal, gluteal, thigh and calf subcutaneous fat. FPLD3 subjects had increased supraclavicular and abdominal subcutaneous fat, with less severe reductions in gluteal, thigh and calf fat compared to FPLD2 subjects. The repartitioning of fat in the HIVPL subject closely resembled that of FPLD3 subjects. APL and CGL subjects had reduced upper body, gluteal and thigh subcutaneous fat; the APL subject had increased, while CGL subjects had decreased subcutaneous calf fat. Visceral fat was markedly increased in FPLD2 and APL subjects.
Semi-automated MRI-based adipose tissue quantification indicates differences between various lipodystrophy types in these studied clinical cases and is a potentially useful tool for extended quantitative phenomic analysis of genetic metabolic disorders. Further studies with a larger sample size are essential for confirming these preliminary findings.
Adipose tissue distribution is an important biomarker associated with metabolic risk . It is important to develop robust high-resolution quantitative non-invasive imaging technologies for both clinical evaluation and research applications of obesity and related metabolic disorders. Magnetic resonance imaging (MRI) technology holds a great promise as a sensitive, replicable, non-invasive and non-irradiating method to image adipose tissue quantity and distribution [1–3]. As with any quantitative methodology, performance must be evaluated at extreme levels of the study analytes. In this regard, lipodystrophy syndromes represent extreme "experiments of nature" [4–7] that can help test the limits of the resolution of MRI for detecting and quantifying subcutaneous fat.
Lipodystrophies are a heterogeneous group of adipose tissue disorders that can be either inherited or acquired [4–8]. They are characterized by selective loss of fat from different anatomical regions [4, 8]. Inherited lipodystrophy syndromes include partial lipodystrophy subtypes 2 and 3 (FPLD2 and FPLD3), which are caused by heterozygous mutations in LMNA and PPARG genes, respectively, and congenital generalized lipodystrophy (CGL) subtypes 1 and 2, which are caused by homozygous mutations in AGPAT2 and BSCL2 genes, respectively [4, 9]. Acquired forms of lipodystrophy include acquired partial lipodystrophy (APL), which is sometimes associated with heterozygous mutations in the LMNB2 gene . Detailed MRI assessments of adipose tissue distribution in these diverse lipodystrophy types have not yet been reported.
We previously reported pilot studies of adipose tissue quantification in the lower extremity from MR images of one patient with FPLD2 and one patient with FPLD3 . While adipose tissue stores in the thigh and calf were markedly reduced in both patients, attenuation of adipose tissue appeared greater in the FPLD2 patient. That small pilot study provided proof-of-principle that combining MRI with semi-automated image analysis could reveal differences even at the extreme low end of the range of fat distribution . We now apply this method to define quantitative and qualitative differences in fat distribution across a range of clinical lipodystrophy syndromes and healthy female controls.
We studied a total of 22 female subjects: 16 were patients with various forms of lipodystrophy and 6 were normal healthy controls, with normal fat distribution clinically and absence of mutations in known lipodystrophy genes. The lipodystrophy patients included 10 subjects with FPLD2, two with FPLD3, one with human immunodeficiency virus (HIV)-associated partial lipodystrophy (HIVPL), one with acquired partial lipodystrophy (APL) and two with congenital generalized lipodystrophy (CGL). All patients consented to provide their medical history, underwent physical examination and provided fasting blood samples. All subjects gave informed consent and the University of Western Ontario Institutional Review Board approved the protocol (#11244).
Bioimpedance analysis (BIA) measurements were determined using the BC-418 Segmental Body Composition Analyzer (Tanita, Arlington Heights, IL) which provided percent fat estimates for the total body and lower extremities. The intra-observer coefficient of variation for BIA measurements was 4.5%.
DNA was prepared from peripheral blood leukocytes (Puregene, Gentra Systems, Minneapolis, MN). DNA sequences of all subjects were screened for mutations in candidate lipodystrophy genes, namely LMNA, PPARG, LMNB2, AGPAT2 and BSCL2, which are causative for FPLD2, FPLD3, APL and the two forms of CGL, respectively (MIM 150330, 601487, 150341, 603100, 606158). Amplified and purified genomic DNA fragments were sequenced using reported exon-specific primers for LMNA , PPARG [5, 13], LMNB2 , BSCL2 and AGPAT2 . Electropherograms were then analyzed using Sequence Navigator v.1.0.1 (Applied Biosystems, Mississauga, ON).
Magnetic resonance imaging
We used scanning and raw MR image acquisition parameters as reported previously . MRI scans were performed on a 1.5T GE MR Medical system (Model: Signa Excite). A neurovascular array coil was used to image the supraclavicular region and an 8-channel receive-only torso array coil was used to image other body regions.
Validation of adipose tissue quantification method
After obtaining the images above, subcutaneous adipose tissue was quantified in both MR and corresponding cryosection images using the method developed in our laboratory . The Pearson correlation coefficient was used to test both intra-observer variation among duplicate blinded MRI and cryosection subcutaneous adipose tissue measurements and also to test the accuracy of fat quantification in MR images in comparison to the anatomically matched cryosection images.
Adipose tissue quantification
All statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC). Mean values between FPLD2 and control groups were compared using student t-tests. A nominal P-value < 0.05 was chosen as the threshold for significance for all statistical comparisons. Pearson correlation coefficients were calculated between percent fat in the lower limb as determined by BIA and MRI methods. The Pearson correlation coefficient was also used to test variation among duplicate blinded subcutaneous adipose tissue measurements made by the same observer on different days in the supraclavicular, abdominal-subcutaneous, abdominal-visceral and gluteal MRI sections (intra-observer variability) and also to test inter-observer variation for the same samples, analyzed by a different observer on different days.
Clinical, biochemical and anthropometric data
Clinical and biochemical profile of 22 female subjects
40 ± 16
48 ± 16
36 ± 15
40 ± 1
26.4 ± 6.73
24.3 ± 2.07
33.9 ± 0.72
23.0 ± 0.08
Molecular genetic basis of disease
LMNA R482Q (all)
PPARG F388L (all)
BSCL2 frameshift (both)
total cholesterol (mM)
4.41 ± 0.54
4.76 ± 1.13
3.80 ± 0.43
4.08 ± 0.78
1.08 ± 0.63
2.62 ± 1.09
1.84 ± 1.27
2.13 ± 0.83
LDL cholesterol (mM)
2.36 ± 0.33
2.59 ± 1.11
2.42 ± 0.59
2.09 ± 0.69
HDL cholesterol (mM)
1.56 ± 0.45
1.01 ± 0.29
1.04 ± 0.44
fasting blood glucose (mM)
4.71 ± 1.14
6.01 ± 1.74
8.35 ± 0.21
6.65 ± 1.34
13.8 ± 13.7
19.0 ± 14.6
29.5 ± 14.9
140 ± 130
apolipoprotein B (g/L)
0.71 ± 0.12
0.90 ± 0.18
0.99 ± 0.43
apolipoprotein A-I (g/L)
1.51 ± 0.38
1.25 ± 0.28
1.04 ± 0.21
systolic blood pressure (mm/Hg)
119 ± 19.2
127 ± 13.7
134 ± 8.49
113 ± 7
diastolic blood pressure (mm/Hg)
70 ± 11.7
73.5 ± 8.9
71.0 ± 8.5
75.0 ± 7.1
waist circumference (cm)
87.0 ± 19.2
87.5 ± 7.9
118 ± 17
77.5 ± 0.7
FPLD2 subjects were each heterozygous for the LMNA R482Q missense mutation . FPLD3 subjects were heterozygous for the PPARG F388L mutation . No mutations were found in any of the candidate genes in the genome of the HIVPL subject. The APL subject was heterozygous for the LMNB2 R215Q missense mutation . The CGL subjects were each homozygous for the frameshift mutation in BSCL2 .
Validation of adipose tissue quantification method
Subcutaneous adipose tissue values were obtained from 5 transaxial locations in the Visible Human male [15, 16] for both MR and cryosection images (Figure 1). The intra-observer correlation coefficients, determined by comparing duplicate blinded measurements of percent subcutaneous fat from the 5 locations, were 0.996 and 0.999 for the MR and cryosection image sets, respectively. The correlation coefficient was 0.999 for the comparison of mean percent subcutaneous adipose tissue values obtained from the MR images and matching cryosection images.
Intra- and inter-observer correlations for quantitative MRI analysis
Intra- and inter-observer correlations for analysis of the mid-calf and mid-thigh were determined previously . Analysis of adipose tissue in the newly investigated compartments, namely the supraclavicular, abdominal-subcutaneous, abdominal-visceral and gluteal sections, was conducted by two independent observers. Intra- and inter-observer correlation coefficients were determined by comparing two replicates from eight study subjects. The intra-observer correlation coefficients were, on average, 0.994, 0.999, 0992, and 0.999 for the supraclavicular, abdominal-subcutaneous, abdominal-visceral and gluteal sections, respectively. The inter-observer correlation coefficients were, on average, 0.997, 0.995, 0.992, and 0.998 for the supraclavicular, abdominal-subcutaneous, abdominal-visceral and gluteal sections, respectively.
Correlation of percent fat in thigh determined by BIA and MRI
MRI quantification of regional fat stores
Comparison of regional mean ± standard deviation percent fat in 10 FPLD2 subjects and 6 normal control subjects
7.34 ± 3.40
4.10 ± 2.42
Abdomen – L4
8.27 ± 4.98
30.9 ± 8.00
12.4 ± 7.70
29.8 ± 10.4
12.7 ± 6.70
38.0 ± 9.80
4.34 ± 4.94
25.4 ± 3.50
Abdomen – L4
35.4 ± 8.60
8.81 ± 7.15
Both FPLD2 and FPLD3 subjects had increased supraclavicular fat (Figure 5a), reflecting the increase in upper body fat observed clinically . The patient with HIVPL also had increased supraclavicular fat, comparable to the FPLD3 patients (Figure 5a). In contrast, supraclavicular fat in the APL subject was not increased and CGL subjects had reduced supraclavicular fat (Figure 5a), consistent with generalized depletion of body fat [4, 20].
FPLD2 and FPLD3 subjects had clear disparities in abdomen-L4 subcutaneous fat (Figure 5b), with a significant decrease and no decease in FPLD2 and FPLD3 subjects, respectively. HIVPL, APL and CGL subjects had varying amounts of subcutaneous adipose tissue at the abdomen-L4 level: no decrease for the HIVPL subject, but markedly decreased for the APL and CGL subjects. Again, the HIVPL patient most closely resembled the FPLD3 subject.
Further disparities between FPLD2 and FPLD3 were seen for visceral adipose tissue at the abdomen-L4 level; visceral fat content was the opposite of the subcutaneous fat distribution at this level (Figure 5c), with a significant increase and no increase in the FPLD2 and FPLD3 subjects, respectively. Thus FPLD2 subjects have more severe depletion of abdominal subcutaneous fat and more pronounced accumulation of visceral fat than FPLD3 subjects. The HIVPL patient had marginally increased visceral adipose tissue, again comparable to the FPLD3 subjects. The APL subject had markedly increased visceral adipose tissue while the CGL subjects showed a range of visceral fat.
Gluteal subcutaneous fat distribution was comparable to the abdomen-L4 distribution (Figure 5d). Gluteal fat in the FPLD2 and FPLD3 subjects was decreased and not decreased, respectively (Figure 5d). The HIVPL subject again closely resembled the FPLD3 subjects (Figure 5d). APL and CGL subjects both showed decreased gluteal fat, with APL having the lowest value (Figure 5d).
The most consistently altered fat depot across all lipodystrophy types was decreased subcutaneous thigh fat (Figure 5e). Similar to other subcutaneous depots, FPLD2 subjects had pronounced depletion of subcutaneous thigh fat, while FPLD3 subjects had less depletion of subcutaneous thigh fat (Figure 5e). A descending trend of adipose tissue amount was observed for subjects with HIVPL, APL and CGL, respectively (Figure 5e). Subcutaneous adipose tissue in HIVPL subject most resembled that of FPLD3 subjects. CGL subjects had nearly no subcutaneous adipose tissue in this region and harbored some of the lowest values from these experiments (Figure 5e).
The pattern of subcutaneous fat distribution in the mid-calf was very similar to that observed in the mid-thigh (Figure 5f). FPLD2 subjects had greater depletion of calf fat than FPLD3 subjects (Figure 5f). The HIVPL patient had reduced fat comparable to the quantity seen in FPLD3 (Figure 5f). In contrast to all other lipodystrophic subjects studied, the APL subject had increased adipose tissue in the calves (Figure 5f). CGL subjects showed the greatest decrease in calf fat (Figure 5f).
In this study of all female subjects we have shown that MRI analysis with quantification of fat depots can reveal differences between patients with various forms of lipodystrophy. Evaluating lipodystrophy patients allowed for assessment of the lower limits of resolution of the method. The main findings include: 1) demonstration of significant differences from controls in FPLD2 subjects, with increased suprvaclavicular and visceral fat and decreased subcutaneous abdominal, gluteal, thigh and calf fat; 2) confirmation of the subjective clinical impression of differences between FPLD2 and FPLD3 subjects, such as no increase in visceral fat, no decrease in abdomen-L4 subcutaneous fat and less dramatic depletion of subcutaneous gluteal, thigh and calf fat in FPLD3 compared with FPLD2 subjects; 3) fat repartitioning in the HIVPL subject resembled the FPLD3 subjects; 4) reduced subcutaneous fat in the upper body, gluteal region and thigh, in both APL and CGL subjects, with increased and decreased calf fat in APL and CGL subjects, respectively; and 5) consistently reduced fat in the mid-thigh across the various lipodystrophy types, suggesting that this analyte could help distinguishing whether a form of lipodystrophy might be present in a patient with in whom the clinical diagnosis is unclear.
Sampling measurements of adipose tissue in specific body regions was an important approach for the identification of adipose tissue distribution differences among lipodystrophic patients. Qualitatively, MR images as well as external phenotypes of different lipodystrophic subjects hint to the loss of fat is specific body regions, such as loss of fat in the extremities and general abdominal-visceral fat accumulation that is seen in the FPLD subjects. Whole-body measurements of adipose tissue [21, 22], is a potential next step in similar future research. While valuable in its ability to represent total body fat, we chose to implement a sampling approach instead of whole-body fat quantification in this pilot study to help focus on the quantitative investigation of adipose tissue distribution.
We observed very high intra- and inter-observer correlation values for the combination of methods, and furthermore, validated the method against an anatomical reference standard. In addition to reproducibility, the described methods yield results quickly and accurately, with minimal user intervention. While the correlation coefficient of percent fat values found by MRI and BIA was statistically significant, the r of 0.52 indicated only modest correlation, suggesting that the two determinations are not interchangeable. BIA appears to measure total limb fat, including both subcutaneous and intramuscular fat, while MRI measures only subcutaneous fat. Acquisition of such values from a larger number of patients with various lipodystrophy subtypes would verify the results observed here. Future application of this quantification method, or another [23–27], may include quantification of fat depots for "garden variety" obesity, metabolic syndrome or diabetes. This approach might also be applicable to quantify metabolically important substrata of fat.
Widespread application of MRI-based fat quantification would require the development of standards with respect to regions surveyed, anatomical landmarks, number of measurements, etc – similar to the consensus standards agreed upon for carotid intima-media thickness measurements using ultrasound. Regional distribution could be an additional MRI analyte that could be considered together with other intermediate traits in subjects with FPLD or even common metabolic syndrome. Quantification of fat depots using MRI and appropriate image analysis software could provide complementary analytes for research and perhaps eventually for the diagnosis and monitoring of interventions.
In summary, we report the expanded use of MRI and image analysis software employing Connected Threshold Grower and Voxel Counter tools to quantify fat depots at multiple sites in patients with several different molecular forms of lipodystrophy. The measurements confirmed the clinical impression that FPLD2 and FPLD3 differ with respect to the extent of subcutaneous fat loss; specifically, subcutaneous fat loss below the umbilicus and visceral fat accumulation in FPLD2 are both greater than in FPLD3. Increasing the sample size of subjects with other forms of lipodystrophy will allow for statistical comparisons. These tools can be applied and might prove useful in quantitative phenotype analysis of other forms of lipodystrophy and in less extreme disorders of fat redistribution or repartitioning, such as "garden variety" or common obesity, insulin resistance, or type 2 diabetes.
Supported by the Jacob J. Wolfe Distinguished Medical Research Chair, the Edith Schulich Vinet Canada Research Chair (Tier I) in Human Genetics, a Career Investigator award from the Heart and Stroke Foundation of Ontario, and operating grants from the Canadian Institutes for Health Research, the Heart and Stroke Foundation of Ontario (NA 5320), the Ontario Research and Development Challenge Fund (Project #0507) and by Genome Canada.
- Garg A: Regional adiposity and insulin resistance. J Clin Endocrinol Metab. 2004, 89 (9): 4206-4210. 10.1210/jc.2004-0631.View ArticlePubMedGoogle Scholar
- Abate N, Burns D, Peshock RM, Garg A, Grundy SM: Estimation of adipose tissue mass by magnetic resonance imaging: validation against dissection in human cadavers. J Lipid Res. 1994, 35 (8): 1490-1496.PubMedGoogle Scholar
- Foster MA, Hutchison JM, Mallard JR, Fuller M: Nuclear magnetic resonance pulse sequence and discrimination of high- and low-fat tissues. Magn Reson Imaging. 1984, 2 (3): 187-192. 10.1016/0730-725X(84)90004-3.View ArticlePubMedGoogle Scholar
- Simha V, Garg A: Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J Clin Endocrinol Metab. 2003, 88 (11): 5433-5437. 10.1210/jc.2003-030835.View ArticlePubMedGoogle Scholar
- Al-Shali K, Cao H, Knoers N, Hermus AR, Tack CJ, Hegele RA: A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy. J Clin Endocrinol Metab. 2004, 89 (11): 5655-5660. 10.1210/jc.2004-0280.View ArticlePubMedGoogle Scholar
- Misra A, Peethambaram A, Garg A: Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore). 2004, 83 (1): 18-34. 10.1097/01.md.0000111061.69212.59.View ArticleGoogle Scholar
- Pandey SN, Pungavkar SA, Vaidya RA, Patkar D, Hegele RA, Sheth FJ, Sheth J, Shah SS, Vaidya AB: An imaging study of body composition including lipodeposition pattern in a patient of familial partial lipodystrophy (Dunnigan type). J Assoc Physicians India. 2005, 53: 897-900.PubMedGoogle Scholar
- Foster DW: The lipodystrophies and other rare disorders of adipose tissue. Harrison's Principles of Internal Medicine. Edited by: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longon DL. 1998, New York , McGraw-Hill, 2209-2214.Google Scholar
- Bhayana S, Hegele RA: The molecular basis of genetic lipodystrophies. Clin Biochem. 2002, 35 (3): 171-177. 10.1016/S0009-9120(02)00297-7.View ArticlePubMedGoogle Scholar
- Hegele RA, Cao H, Liu DM, Costain GA, Charlton-Menys V, Rodger NW, Durrington PN: Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy. Am J Hum Genet. 2006, 79 (2): 383-389. 10.1086/505885.View ArticlePubMedPubMed CentralGoogle Scholar
- Al-Attar SA, Pollex RL, Robinson JF, Miskie BA, Walcarius R, Rutt BK, Hegele RA: Semi-automated segmentation and quantification of adipose tissue in calf and thigh by MRI: a preliminary study in patients with monogenic metabolic syndrome. BMC Med Imaging. 2006, 6: 11-10.1186/1471-2342-6-11.View ArticlePubMedPubMed CentralGoogle Scholar
- Cao H, Hegele RA: Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet. 2000, 9 (1): 109-112. 10.1093/hmg/9.1.109.View ArticlePubMedGoogle Scholar
- Hegele RA, Cao H, Frankowski C, Mathews ST, Leff T: PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes. 2002, 51 (12): 3586-3590. 10.2337/diabetes.51.12.3586.View ArticlePubMedGoogle Scholar
- Bhayana S, Siu VM, Joubert GI, Clarson CL, Cao H, Hegele RA: Cardiomyopathy in congenital complete lipodystrophy. Clin Genet. 2002, 61 (4): 283-287. 10.1034/j.1399-0004.2002.610407.x.View ArticlePubMedGoogle Scholar
- Spitzer V, Ackerman MJ, Scherzinger AL, Whitlock D: The visible human male: a technical report. J Am Med Inform Assoc. 1996, 3 (2): 118-130.View ArticlePubMedPubMed CentralGoogle Scholar
- The Visible Human Project- AnatQuest Anatomic Images Online. [http://vhnet.nlm.nih.gov/]
- ImageJ: Image processing and analysis in Java. [http://rsb.info.nih.gov/ij]
- Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001, 285 (19): 2486-2497. 10.1001/jama.285.19.2486.Google Scholar
- Hegele RA: Lessons from human mutations in PPARgamma. Int J Obes (Lond). 2005, 29 Suppl 1: S31-5. 10.1038/sj.ijo.0802911.View ArticleGoogle Scholar
- Hegele RA: Genetic Lipodystrophies: Models for Insulin Resistance. Curr Med Chem - Imun, Endoc & Metab Agents. 2002, Bentham Science Publishers Ltd., 245-250. 10.2174/1568013023358799.Google Scholar
- Kullberg J, Angelhed JE, Lonn L, Brandberg J, Ahlstrom H, Frimmel H, Johansson L: Whole-body T1 mapping improves the definition of adipose tissue: consequences for automated image analysis. J Magn Reson Imaging. 2006, 24 (2): 394-401. 10.1002/jmri.20644.View ArticlePubMedGoogle Scholar
- Machann J, Thamer C, Schnoedt B, Haap M, Haring HU, Claussen CD, Stumvoll M, Fritsche A, Schick F: Standardized assessment of whole body adipose tissue topography by MRI. J Magn Reson Imaging. 2005, 21 (4): 455-462. 10.1002/jmri.20292.View ArticlePubMedGoogle Scholar
- Gronemeyer SA, Steen RG, Kauffman WM, Reddick WE, Glass JO: Fast adipose tissue (FAT) assessment by MRI. Magn Reson Imaging. 2000, 18 (7): 815-818. 10.1016/S0730-725X(00)00168-5.View ArticlePubMedGoogle Scholar
- Lancaster JL, Ghiatas AA, Alyassin A, Kilcoyne RF, Bonora E, DeFronzo RA: Measurement of abdominal fat with T1-weighted MR images. J Magn Reson Imaging. 1991, 1 (3): 363-369. 10.1002/jmri.1880010315.View ArticlePubMedGoogle Scholar
- Armao D, Guyon JP, Firat Z, Brown MA, Semelka RC: Accurate quantification of visceral adipose tissue (VAT) using water-saturation MRI and computer segmentation: preliminary results. J Magn Reson Imaging. 2006, 23 (5): 736-741. 10.1002/jmri.20551.View ArticlePubMedGoogle Scholar
- Positano V, Gastaldelli A, Sironi AM, Santarelli MF, Lombardi M, Landini L: An accurate and robust method for unsupervised assessment of abdominal fat by MRI. J Magn Reson Imaging. 2004, 20 (4): 684-689. 10.1002/jmri.20167.View ArticlePubMedGoogle Scholar
- Demerath EW, Ritter KJ, Couch WA, Rogers NL, Moreno GM, Choh A, Lee M, Remsberg K, Czerwinski SA, Chumlea WC, Siervogel RM, Towne B: Validity of a new automated software program for visceral adipose tissue estimation. Int J Obes (Lond). 2007, 31 (2): 285-291. 10.1038/sj.ijo.0803409.View ArticleGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2342/7/3/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.